Loading...
XNASEXAS
Market cap10bUSD
Jan 03, Last price  
57.25USD
1D
0.57%
1Q
-16.25%
Jan 2017
328.52%
Name

Exact Sciences Corp

Chart & Performance

D1W1MN
XNAS:EXAS chart
P/E
—
P/S
4.24
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.07%
Rev. gr., 5y
40.63%
Revenues
2.50b
+19.93%
4,935,0004,250,0004,750,0002,935,000-867,0004,758,0005,344,0004,163,0004,144,0004,144,0001,798,00039,437,00099,376,000265,989,000454,462,000876,293,0001,491,391,0001,767,087,0002,084,279,0002,499,766,000
Net income
-204m
L-67.26%
-18,523,000-14,520,000-12,915,000-11,959,000-9,741,000-9,089,000-11,556,000-28,675,000-52,421,000-46,514,000-100,048,000-157,803,000-167,211,000-114,397,000-175,149,000-83,993,000-848,533,000-595,625,000-623,506,000-204,149,000
CFO
156m
P
-21,174,000-15,982,000-12,154,000-8,767,000-7,904,000-12,640,000-13,478,000-27,824,000-44,155,000-39,295,000-80,912,000-134,017,000-130,066,000-71,724,000-69,325,000-115,010,000136,482,000-102,236,000-223,559,000156,119,000
Earnings
Feb 19, 2025

Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
URL
https://www.exactsciences.com/
IPO date
Jan 30, 2001
Employees
6,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,499,766
19.93%
2,084,279
17.95%
Cost of revenue
2,700,430
2,551,127
Unusual Expense (Income)
NOPBT
(200,664)
(466,848)
NOPBT Margin
Operating Taxes
2,403
(9,064)
Tax Rate
NOPAT
(203,067)
(457,784)
Net income
(204,149)
-67.26%
(623,506)
4.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,885
32,015
BB yield
-0.45%
-0.37%
Debt
Debt current
79,379
28,366
Long-term debt
2,665,795
2,600,904
Deferred revenue
(488,262)
Other long-term liabilities
335,982
352,459
Net debt
1,967,530
1,949,716
Cash flow
Cash from operating activities
156,119
(223,559)
CAPEX
(124,190)
(214,462)
Cash from investing activities
49,679
74,066
Cash from financing activities
159,766
76,485
FCF
(193,370)
(555,070)
Balance
Cash
777,644
632,057
Long term investments
47,497
Excess cash
652,656
575,340
Stockholders' equity
(3,465,932)
(3,268,482)
Invested Capital
9,501,944
8,622,712
ROIC
ROCE
EV
Common stock shares outstanding
180,144
176,351
Price
73.98
49.42%
49.51
-36.39%
Market cap
13,327,053
52.64%
8,731,138
-34.53%
EV
15,294,583
10,680,854
EBITDA
5,944
(269,290)
EV/EBITDA
2,573.11
Interest
24,421
19,634
Interest/NOPBT